G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of ($0.92), $0.10 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $10.57 million versus the consensus estimate of $9.09 million.

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18